T AND TN PANCARCINOMA MARKERS - AUTOANTIGENIC ADHESION MOLECULES IN PATHOGENESIS, PREBIOPSY CARCINOMA-DETECTION, AND LONG-TERM BREAST-CARCINOMA IMMUNOTHERAPY

被引:87
作者
SPRINGER, GF
机构
[1] CHICAGO MED SCH, DEPT SURG, HEATHER M BLIGH CANC RES LABS, N CHICAGO, IL 60064 USA
[2] NORTHWESTERN UNIV, CTR CANC, CHICAGO, IL 60611 USA
来源
CRITICAL REVIEWS IN ONCOGENESIS | 1995年 / 6卷 / 01期
关键词
T TN PANCARCINOMA ANTIGENS; AUTOIMMUNE RESPONSES TO CARCINOMA T TN ANTIGENS; PRECLINICAL CARCINOMA DETECTION BY T ASSAYS; T AND TN EPITOPES IN CARCINOMA PATHOGENESIS; T TN EPITOPES IN CELL ADHESION; DELAYED-TYPE SKIN HYPERSENSITIVITY TO T TN ANTIGEN; HUMORAL RESPONSE TO T ANTIGEN; EFFICACIOUS T TN ANTIGEN CARCINOMA VACCINE;
D O I
10.1615/CritRevOncog.v6.i1.50
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Physical and chemical nature of the T and Tn pancarcinoma [CA] glycopeptide epitopes [EPs], which are immediate precursors of the blood group MN EPs, and their role in CA pathogenesis and in clinical disease are discussed. T/Tn are immuno-occluded in non-CA diseased and in healthy tissues. Well-differentiated CAs usually express a higher proportion of T than Tn EPs, while Tn predominates in poorly differentiated primary CAs. Measurement of density of T and Tn EP expression on primary breast CA permits disease prognostication. CA-T and -Tn are cell adhesion molecules involved not only in invasion but also in metastasis. Immunological methods readily detect in vivo autoimmune responses to CA-T and -Tn EPs in about 90% of all CA patients from incipience and throughout. Everyone has preexisting anti-T and anti-Tn antibodies [Abs] induced by the intestinal flora. T/anti-T immunoassays are highly efficient in detection of incipient and clinically overt CAs and, importantly, predicted CA in 77% of the patients, months to many years before their biopsy/X-ray turned positive; there were no false immune predictions of CA. Since 1974, we use human O MN red cell-derived T/Tn glycoprotein vaccine plus adjuvants successfully in safe, specific, effective, long-term, active immunotherapy against recurrence of advanced breast CA pTNM Stages IV, III, and II.
引用
收藏
页码:57 / 85
页数:29
相关论文
共 238 条
[41]  
DESAI PR, 1995, IN PRESS J IMMUNOL M
[42]   RECENT DEVELOPMENTS IN THE MOLECULAR-GENETIC UNDERSTANDING OF BREAST-CANCER [J].
DEVILEE, P ;
SCHUURING, E ;
VANDEVIJVER, MJ ;
CORNELISSE, CJ .
CRITICAL REVIEWS IN ONCOGENESIS, 1994, 5 (2-3) :247-270
[43]   IMMUNOGENICITY OF SYNTHETIC PEPTIDES RELATED TO THE CORE PEPTIDE SEQUENCE ENCODED BY THE HUMAN MUC1 MUCIN GENE - EFFECT OF IMMUNIZATION ON THE GROWTH OF MURINE MAMMARY ADENOCARCINOMA CELLS TRANSFECTED WITH THE HUMAN MUC1 GENE [J].
DING, L ;
LALANI, E ;
REDDISH, M ;
KOGANTY, R ;
WONG, T ;
SAMUEL, J ;
YACYSHYN, MB ;
MEIKLE, A ;
FUNG, PYS ;
TAYLORPAPADIMITRIOU, J ;
LONGENECKER, BM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (01) :9-17
[44]   PEPTIDE MOIETY OF HUMAN-BLOOD-GROUP ACTIVE GLYCOPROTEINS ASSOCIATED WITH ABO AND LEWIS GROUPS [J].
DONALD, ASR ;
CREETH, JM ;
MORGAN, WTJ ;
WATKINS, WM .
BIOCHEMICAL JOURNAL, 1969, 115 (01) :125-&
[45]  
DUPONT MADELEINE, 1934, ARCH INTERNAL MED EXP, V9, P133
[46]  
EHRLICH P, 1909, NED T GENEESK, V5, P274
[47]  
Fisher E R, 1980, Pathol Annu, V15, P239
[48]  
FISHER ER, 1990, CANCER, V65, P2121, DOI 10.1002/1097-0142(19900501)65:9+<2121::AID-CNCR2820651408>3.0.CO
[49]  
2-M
[50]  
FLETCHER MA, 1982, J IMMUNOL, V128, P976